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All-trans-retinoic acid (ATRA) is a physiologically active metabolite of vitamin A. Its antitumour activities have been extensively
studied in a variety of model systems and clinical trials; however, to date the only malignancy responsive to ATRA treatment is
acute promyelocytic leukaemia (APL) where it induces complete remission in the majority of cases when administered in
combination with light chemotherapy and/or arsenic trioxide. After decades of studies, the efficacy of ATRA to treat other acute
myeloid leukaemia (AML) subtypes and solid tumours remains poor. Recent studies directed to improve ATRA responsiveness in
non-APL AML seem to indicate that the lack of effective ATRA response in these tumours may be primarily due to aberrant
epigenetics, which negatively affect ATRA-regulated gene expression and its antileukaemic activity. Epigenetic reprogramming
could potentially restore therapeutic effects of ATRA in all AML subtypes. This review discusses the current progresses in the
understanding how ATRA can be utilised in the therapy of non-APL AML and other cancers.
Shortly after the discovery of vitamin A (retinol) in 1913, scientists
began to realise the extreme importance of this simple fat-soluble
molecule in a large number of complex and diverse physiological
processes in vertebrates. All-trans-retinoic acid (ATRA) was
identified as a key physiologically active metabolite of vitamin A.
The understanding of how ATRA exerts its highly pleiotropic
effects in vertebrates, as well as its antitumour activities, remained
unclear until the discovery of nuclear retinoic acid receptors.
Retinoic acid receptors were shown to be members of the
superfamily of steroid/thyroid hormone nuclear receptors func-
tioning primarily as ligand-inducible transcription factors.
RETINOIC ACID RECEPTORS
Similarly to other key developmental regulators, RARs possess the
capacity to function as a molecular switch; when not bound by
ligand, they form a complex with co-repressors such as N-CoR
(negative co-regulator) or SMRT (silencing mediator for retinoid
and thyroid hormone receptors), and histone deacetylases
(HDACs) to actively inhibit gene expression (Figure 1). Upon
ATRA binding, co-repressors are released and co-activators,
including histone acetyltransferases (HATs), DRIP/TRAP/ARC,
or mediator-containing complexes are recruited to decompress
chromatin and activate transcription of target genes (Glass and
Rosenfeld, 2000). To date, three different RAR and retinoid X (or
rexinoid) receptor (RXR) genes have been characterised (RARA,
RARB, and RARG), each encoding multiple N-terminal protein
isoforms. Retinoid X (or rexinoid) receptors, which bind 9-cis-
retinoic acid (9-cis-RA) with high affinity, serve as obligatory
heterodimerisation partners for RARs. RARA, in common with
other RAR genes, encodes two major isoforms (Figure 1) that differ
in their A region sequence that contribute to transcriptional
regulation in a ligand-independent and promoter-specific manner
(Leid et al, 1992). These isoforms are identical in their B to F
region sequence, which contain DNA (DBD) and ligand binding
(LBD) domains as well as structural motifs responsible for
dimerisation, co-repressor interaction, and ligand-dependent
trans-activation. Expression of the RARa2, RARb2 and possibly
also RARg2 isoforms is under control of promoters that are
inducible by ATRA. Activation of transcription by RARs is
intrinsically linked to their proteasome-mediated degradation
(Giannı` et al, 2002) and upregulation of RARa2, RARb2, and
RARg2 isoform expression by ATRA may therefore have been
evolutionarily selected and conserved to renew expression of a
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given receptor to sustain gene activation and the physiological
effects of ATRA over an extended period of time.
NON-GENOMIC EFFECTS OF ATRA
Similar to other nuclear receptor ligands ATRA can also function,
via so-called non-genomic pathways, independent of the classical
mechanism of nuclear receptor action. All-trans-retinoic acid can
effectively and rapidly modulate the activities of proteins involved
in signal transduction in a manner that is highly cell type specific.
The activation of multiple kinase signalling pathways leads to
transcriptional effects independent of nucleolar RARs via
transcription factors that lie at the end of these signalling cascades
(Al Tanoury et al, 2013; see Figure 2). For example, in neuronal
cells, ATRA has been shown to activate Erks via PI3K and
Src kinases leading to repression of the antidifferentiative
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Figure 1. Structure and function of the retinoic acid receptor alpha gene and protein upon binding of RA. (A) RARA, in common with other RAR
genes, encodes two major isoforms that differ in their promoters (P1 and P2) and A region sequences, but are identical in their B–F region
sequences. The B–F regions contain DNA (DBD) and ligand binding (LBD) domains as well as structural motifs responsible for dimerisation,
co-repressor interaction and ligand-dependent trans-activation. (B) Schematic representation of the RARa LBD, which is composed of 12 alpha
helices (colour coded and labelled as H1–H12). The ribbon diagrams of the crystal structures of un-liganded RXRa LBD (3A9E) and the liganded
RARa LBD (3KMR) are illustrating the principle of RAR activation. In the un-liganded state, helices H3 and H4 provide a binding site for
co-repressors. Upon ligand binding H3 and H4 undergo conformational changes leading to a destruction of the co-repressor binding site.
Helix H12 moves towards a ligand binding pocket and generates a defined binding surface for co-activators such as p160. (C) RARs possess the
capacity to function as a molecular switch; when not bound by ligand, they complex with co-repressors, such as N-CoR or SMRT, and HDACs
to actively inhibit gene expression. Upon ATRA binding, co-repressors are released and co-activators, including DRIP/TRAP/ARC or
mediator-containing complexes as well as HATs, are recruited to decompress chromatin and activate transcription of target genes.
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octamer-binding transcription factor 4 (Oct4). In epithelial cells
and fibroblasts, RARa can form complexes and activate G protein
alpha Q (Gaq) in response to ATRA. Activation of Gaq in
turn leads to the activation of RhoGTPase, p38MAPK, and
MSK1. Phospho-MSK1 then contributes to transcriptional
activation of RARa target genes by phosphorylation of histones
and RARa itself.
Another non-genomic effect of ATRA is that it can rapidly lead
to the accumulation of cyclic adenosine monophosphate (AMP) in
acute promyelocytic leukaemia (APL), most likely by adenyl
cyclase stimulation and protein kinase A (PKA) activation.
Activated PKA can phosphorylate and activate RARa leading to
increased expression of RAR target genes and differentiation. In
addition, ATRA has been shown to upregulate the granulocyte
colony-stimulating factor (G-CSF) and granulocyte macrophage
colony-stimulating factor (GM-CSF) receptor resulting in the
amplification of the MAP kinase pathway via a positive feedback-
loop mechanism (Glasow et al, 2005). Therefore, in normal
myelomonocytic differentiation ATRA and growth factor (GF)
signalling converge via common signalling cascades to affect
activities of RARs as well as other transcription factors.
The activity of ATRA in leukaemia cells is dependent on
complex interactions between genomic and non-genomic path-
ways. Although much remains to be understood regarding the
exact mechanisms underlying the non-genomic effects of ATRA, it
is clear that these effects have important consequences and have to
be taken into consideration when evaluating the overall response of
a particular cell type to retinoids.
ATRA IN APL
Defective or aberrant differentiation is a hallmark of many cancers.
It is caused by various mutations that disrupt signalling pathways,
epigenetic modifiers, and transcription factors leading to the
deregulation of the expression of proteins required for differentia-
tion. Terminal differentiation results in the loss of long-term
proliferative capacity and eventually induction of apoptosis. The
potential of ATRA to force the completion of disrupted maturation
programs underlies the concept of differentiation therapy.
Differentiation therapy offers the prospect of a less aggressive
treatment coupled to limited damage to normal cells.
Breitman et al (1980) showed that the HL-60 cell line, which
was allegedly derived from a patient with APL, could be induced to
undergo granulocytic differentiation by micromolar concentrations
of ATRA. One year later, the same group of investigators showed
that ATRA causes primary APL cells to differentiate in vitro.
Although an obvious step forward, the clinical trial with ATRA did
not immediately follow and it was only in 1987 that Huang and
colleagues reported the successful use of ATRA to induce complete
remission (CR) in patients with APL, without an apparent increase
in the severity of the haemorrhagic diathesis observed at
presentation (Huang et al, 1987). Incorporation of chemotherapy
and up-front use of ATRA in combination with arsenic trioxide
(ATO) lead to CR rates in excess of 93% with patients achieving
5-year overall survival rates approaching 100%. A recent phase
3 trial showed that combination treatment of ATRA and ATO
without chemotherapy leads to CR and an extended overall
survival compared with the standard ATRA and chemotherapy
treatment (P¼ 0.02) in patients with low-risk APL (Lo-Coco et al,
2013). This success of ATRA in APL shows that the concept of
differentiation therapy can be an effective strategy in leukaemia
and provided a rationale for its use in the treatment of other
cancers. The discovery that the t(15;17) translocation, the
cytogenetic marker for APL involves the RARA gene on
chromosome 17q21, reaffirmed the importance of ATRA and
RARa in myelomonocytic differentiation and paved the way for the
understanding of the molecular mechanisms underlying the disease
pathogenesis as well as this remarkable response to ATRA (Sirulnik
et al, 2003).
The most common RARA translocation partner is the PML
gene. Fusion of PML sequences to the B-F regions of RARA
increases the affinity of the fusion receptor for co-repressors so that
higher (pharmacological) levels of ATRA are required to induce its
dissociation. Consistent with these findings, ability of PML/RARa
to block differentiation of transfected myeloid cells depends on an
intact N-CoR-binding region in the RAR moiety of the fusion
protein (Racanicchi et al, 2005).
ATRA IN NON-APL AML AND OTHER MALIGNANCIES
The seemingly selective effectiveness of ATRA in APL poses an
important question of whether the presence of the PML/RARa
rearrangements in this malignancy renders it uniquely susceptible
to ATRA therapy. One argument against such a view is that ATRA
effectiveness in AML has been observed in cells that lack PML/
RARa, as HL-60 cells, that can be induced to differentiate into
mature granulocytes (Breitman et al, 1980). Furthermore, clinical
studies with ATRA in previously untreated older patients with
AML yielded some encouraging results and various clinical trials
throughout the World have shown effectiveness of ATRA when
used in combination with other agents such as conventional
chemotherapy. Di Febo et al (2007) found that treatment with
low-dose cytosine arabinoside (LDAC) and ATRA lead to an
improvement of the time to treatment failure rate and longer
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Figure 2. Non-genomic effects of ATRA. (A) A fraction of the cellular
RARa pool is present in membrane lipid rafts, where it forms complexes
with G protein alpha Q (Gaq) in response to RA. Activation of Gaq leads
to activation of RhoGTPase, p38MAPK and MSK1 in epithelial and
fibroblast cells. Phospho-MSK1 contributes to transcriptional activation
of RARa target genes by phosphorylation of histones and RARa itself.
(B) In neuronal cells, RA was shown to activate Erks via PI3K/RARa and
Src/RARg. Downstream effectors of Erks are still unknown, but in RA-
treated P19 cells, the activated Erks phosphorylate testicular nuclear
receptor 2 (TR2) that then becomes a repressor of the octamer-binding
transcription factor 4 (Oct4) gene, thus facilitating the differentiation
program that is expected to take place in response to RA. (C) RA leads
to a rapid response to cyclic adenosine monophosphate (AMP)
accumulation in APL cells, most likely by stimulation of adenyl cyclase,
leading to protein kinase A (PKA) activation and enhanced expression
of RAR target genes and differentiation.
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survival in patients with AML older than 60 years in comparison
with LDAC alone (Di Febo et al, 2007). Similarly, Schlenk et al
(2009) reported that in elderly patients with AML the genotype
‘mutant NPM1 without FLT3-ITD’ appears to be a predictive
marker for response to ATRA given in addition to intensive
chemotherapy. Venditti et al (1995) also observed that the
combined use of ATRA and LDAC was effective for inducing
CR in patients with ‘poor prognosis’ AML, especially in patients
with o50% bone marrow infiltration (Venditti et al, 1995).
However, other phase 2 studies showed no or non-significant
effects (Milligan et al, 2006; Burnett et al, 2007). Overall, these
studies show that the efficacy achieved so far with ATRA in
patients with non-APL AML is limited and there is much room for
improvement.
Use of ATRA in anticancer therapy. Given the specific role of
ATRA in cell proliferation and differentiation, its potential
effectiveness to treat human cancers has captivated researchers
for decades. Effects of ATRA on tumour development are extensive
and include differentiation and apoptosis induction, as well as
tumour prevention (Altucci and Gronemeyer, 2001). For example,
the ATRA derivative 13-cis-retinoic acid (13-cis-RA) is successfully
used in the treatment of children with high-risk neuroblastoma,
reducing the risk of recurrence after high-dose chemotherapy and
stem cell transplantation and increasing long-term survival
(Matthay et al, 2009). Nevertheless, so far ATRA is only routinely
and effectively used to treat APL and precancerous lesions such as
leukoplakia, actinic keratosis, and cervical dysplasia.
Consistent with the important role of ATRA signalling in
cellular homeostasis and potential tumorigenic consequences of
deregulation in this signalling pathway are reports by Losson and
colleagues showing that loss of Tif1 alpha renders RARa oncogenic
in the liver (Khetchoumian et al, 2008).
In recent years, ATRA has been studied in combinations with
other drugs in a variety of cancers and precancerous conditions.
Currently, several clinical trials using ATRA as part of combination
therapies are ongoing. Tamoxifen, an antioestrogen with anti-
proliferative effects, is more effective against breast carcinoma and
hepatoma cells when combined with retinoids. The combination of
dexamethasone and ATRA has also been shown to inhibit
proliferation and induce differentiation in human osteosarcoma
cells. It has also been observed that Vitamin D3 analogues
combined with ATRA can reduce the breast tumour mass in nude
mice and inhibit cell growth and induce apoptosis in lung, prostate,
breast, and ovarian cancer cells in vitro. In addition, the use of
retinoids against secondary liver cancer, aerodigestive malignancies
and secondary breast cancer has shown promising results (Clarke
et al, 2004).
All-trans-retinoic acid has also been evaluated in combination
with G-CSF and GM-CSF. All-trans-retinoic acid and G/GM-CSF
co-operate to promote myelomonocytic differentiation in murine
pluripotent myeloid progenitor cells, different AML cell lines, as
well as primary cells from patients with myeloid leukaemia (Matsui
et al, 2005). The ligand-dependent activities of endogenous and
transiently expressed RARa isoforms are enhanced by G/GM-CSF
and correlate with an increased expression of ATRA inducible
genes as well as leukaemic cell differentiation (Glasow et al, 2005).
These data suggest that the manipulation with small molecules of
the signalling pathways downstream from the G/GM-CSF
receptors in AML cells may be an effective strategy to maximise
the effects of ATRA in AML therapy.
Another way to enhance ATRA-stimulated differentiation is the
use of inhibitors of inosine 50-monophosphate dehydrogenase
(IMPDH). Inosine 50-monophosphate dehydrogenase has an
important role in the maintenance of homeostasis of guanosine
nucleotides in the cell. Higher levels of guanosine nucleotides as
well as IMPDH can be found in many cell types, including myeloid
cells, and depletion of guanosine nucleotides are known to
accompany their differentiation.
The use of telomerase inhibitors has also been proposed to
improve ATRA responsiveness. Recent studies suggest that one of
the effects of ATRA and ATO in APL is due to a synergy at the
level of inhibition of telomerase activity. Stem cells exhibit higher
telomerase activity compared with their normal counterparts and
downregulation of the hTERT gene and a concomitant reduction
in telomerase activity is an early event following induction of
differentiation by ATRA. Finally, combination of ATRA with
different interferons (IFNs) have been shown to enhance effects of
both drugs and lead to growth suppression and cell death in many
tumour cell lines via a set of genes associated with retinoid-IFN-
induced mortality’ (GRIMs) (Hofmann et al, 1998).
Many mutations involving genes that mediate signalling path-
ways have a crucial role in tumorigenesis. These genes contribute
to cell proliferation (e.g., FLT3, c-KIT, RAS, and PTPN11), are
involved in differentiation (e.g., AML1 and CEBPA), or are
implicated in cell-cycle regulation or apoptosis (e.g., P53 and
NPM1). Despite them being ideal partners for ATRA, only a few
treatments combining ATRA with inhibitors of signal transduction
pathways have been described to date. In one study, it has been
observed that the inhibition of the mitogen-activated protein
kinase (MAPK) pathway sensitises AML cells with constitutive
MAPK activation to retinoid- and chemotherapy-induced apopto-
sis (Milella et al, 2001). It has been observed in another study that
RAD001 (everolimus), an inhibitor of mammalian target of
rapamycin complex 1 (mTORC1), is able to reduce the stem cell
potential and enhance the ATRA-induced growth arrest and
differentiation of AML cells. Furthermore, RAD001 improves the
ability of ATRA to inhibit the proliferation of HL-60 cells growing
as tumour xenografts in immune-deficient nude mice (Nishioka
et al, 2009). Inhibitors of the glycogen synthase kinase 3 (GSK3)
have also been shown to inhibit growth and drive differentiation of
a variety of leukaemic cells in combination with ATRA. GSK3b
phosphorylates RARa on multiple residues reducing its transcrip-
tional activity. The inhibition of GSK3b prevents RARa phosphor-
ylation and its degradation by the proteasome leading to increased
levels of RARa in the cell. So far only the FMS-like tyrosine kinase
3 (FLT3) inhibitor midostaurin- and cladribine-based induction
chemotherapy (CLAG) have been studied in a clinical trial in
combination with ATRA in relapsed or refractory AML.
Another way to improve responsiveness to ATRA is to increase
its intracellular levels by inhibiting the activity of the aldoketo-
reductase AKR1C3. AKR1C3 is an NADPD-dependent oxido-
reductase that has a role in the metabolism of retinoids and can
therefore control the level of ATRA in the cell. Acute myeloid
leukaemia cells have been shown to express AKR1C at high levels
and inhibition of AKR1C leads to increased responsiveness of
AML cells to ATRA (Brown and Hughes, 2012).
Epigenetic regulation of RARA and combinatorial use of
Epi-drugs and ATRA. The promoter of the RARA isoform
RARA2, but not RARA1, is hypermethylated in AML cell lines,
and induction of differentiation and expression of RARA2 can be
stimulated with DNA demethylating agents and ATRA treatment.
Consistent with what has been observed in cell lines, levels of RARa2
expression are also markedly reduced in AML patient samples
compared with normal myeloid cells expressing CD33 or CD34.
However, in contrast to AML cell lines and normal myeloid cells,
expression of the RARa1 isoform is also significantly reduced in
primary AML cells. Moreover, both RARA1 and RARA2 promoters
(Glasow et al, 2008) are unmethylated in AML patient samples, while
histones associated with the RARA2 promoter have decreased levels
of overall acetylation of histone H3 and decreased levels of di-
methylation of histone H3 lysine 4. Both are heterochromatin
markers associated with reduced gene expression indicating that
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epigenetically driven decrease in RARA expression may be a factor in
the pathogenesis of AML and contribute to the differentiation
blockade.
Many mutations contribute to tumorigenesis by causing
transcriptional deregulation through epigenetic modifications
resulting in aberrant proliferation, impaired differentiation, and
impaired apoptosis. These epigenetic modifications include
changes in DNA methylation and histone modifications such as
acetylation and methylation. Some studies have indicated that the
combination of ATRA and epigenetic (epi)-drugs such as DNA
methyltransferase inhibitors (DNMTi) or histone deacetylase
inhibitors (HDACi) has higher therapeutic value in AML disease
and potentially in other malignancies (Figure 3). Aberrant CpG
island methylation in promoter regions in genes coding for tumour
suppressors is a well-described phenomenon. CpG island methyla-
tion is associated with transcriptional silencing, involving the
recruitment of methyl-binding proteins and HDACs to regions
close to transcriptional initiation sites (Garcia-Manero et al, 2009).
Over the last years, several epigenetic drugs have been approved
or are in clinical development (Dawson and Kouzarides, 2012).
Two of the first epigenetic drugs used in AML were the nucleoside
analogues 5-azacytidine and 5-aza-20deoxycytidine. These DNMTi
are incorporated into the DNA, where they form a covalent
complex with the DNMT enzyme. This results in the degradation
of the enzyme and a progressive loss of DNMT activity and the
aberrant CpG island hypermethylation in cancer cells. Histone
deacetylase inhibitors have been demonstrated to suppress
tumours with t(15;17) translocations in nude mice, and induce
remission in transgenic mouse models of ATRA-resistant APL (He
et al, 2001). Histone deacetylase inhibitors also induce differentia-
tion and apoptosis of t(8;21) leukaemia cell lines and primary
leukaemia blasts (Wang et al, 1999). Although HDACi have been
used both alone and in combination with ATRA in patients with
AML (including APL) the results were of limited value. One reason
could be that these agents fail to clear leukaemia-initiating cells
(LICs) (Leiva et al, 2012). An interesting new approach to
specifically target the repressive PML-RARa-HDAC complex in
APL has been recently published by Bellis et al (2014). Using a
hybrid molecule of ATRA with a 2-aminoanilide tail of the HDAC
inhibitor MS-275 (MC2392), they were able to selectively induce
apoptosis in cells carrying the PML-RARa fusion gene.
We have recently demonstrated a critical role for the histone H3
lysine 4 mono/di (H3K4me1/me2) demethylase LSD1 (KDM1A,
AOF2) as a negative regulator of the ATRA-mediated myeloid
differentiation pathway (Schenk et al, 2012). LSD1 is highly
expressed in AML patients (www.proteinatlas.org) and its over-
expression has been correlated with impaired survival in various
other tumours (Hayami et al, 2011). Overexpression of LSD1 in
AML is associated with alterations in the histone methylation status
and repression of ATRA-responsive genes. We showed that
combination treatments with inhibitors of LSD1 and ATRA can
dramatically enhance the pro-differentiative effects of ATRA in vitro
and in vivo. Co-treatment with ATRA and tranylcypromine (TCP)
greatly increased the fraction of CD11bþ cells by 21-fold and 16-
fold in HL-60 and TEX cells, respectively. Mirroring the results in
cell lines, co-treatment with ATRA and TCP increased the fraction
of CD11bþ cells in primary AML patient samples by a factor up to
11-fold and induced morphological changes, including formation of
cytoplasmic neutrophil granules, consistent with differentiation of
patient blasts into polymorphonuclear leukocytes. The treatment
also lead to diminished clonogenic capacity of AML cells in vitro and
engraftment of primary AML cells from patients in vivo in
NOD.SCID gamma (NSG) mice, suggesting that LSD1i/ATRA
combinations may also target LICs. We showed that these effects are
at least in part due to gene-specific increases in H3K4me2
methylation leading to expression of a subset of genes associated
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Figure 3. Mechanism of action of ATRA/epi-drug combinations. (A) Retinoic acid receptors, not bound by ligand, complex with co-repressors and
HDACs to actively inhibit gene expression. Cancerous cells such as leukaemia initiating cells (LICs) are frequently characterised by activating
mutations or an overexpression of epigenetic regulators (DNMTs, HMTs, HDMs, and HDACs) causing a false repression of tumour suppressor
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with the myelomonocytic differentiation pathway. This work shows
that LSD1 is an important therapeutic target and highlights the
potential for drugs targeting aberrant epigenetics in combination
with retinoids (Figure 3).
Several major pharmaceutical companies are currently devel-
oping selective LSD1 inhibitors with micromolar potency and
activity against a panel of cancer cell lines (Cain, 2012). Phase I
trials evaluating treatment with LDS1 inhibitors in several
hematologic malignancies are expected to begin this year.
FUTURE OF ATRA IN CANCER THERAPY?
Despite important advances in cancer therapeutics over the past
few decades, treatment failure, relapse. and mortality rates in the
majority of malignant diseases, including non-APL AML, remain
unacceptably high. It is reasonable to predict that cure rates will
not improve significantly unless alternative treatment modalities to
conventional chemotherapy regimens and bone marrow trans-
plantation are developed. Treatment of AML with targeted
therapies is particularly promising due to the fact that AMLs have
far fewer mutations than most other adult cancers, with an average
of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas
Research Network, 2013). The availability of relatively inexpensive
new techniques with which cancer-causing mutations in individual
patients can be analysed, open the possibility for personalised
anticancer therapies. Therefore, the goal has to be the development
of a toolbox of drugs that can be used in a personalised manner.
All-trans-retinoic acid is a promising compound for treatment
of a variety of cancers because of its specific effects on cell
proliferation, differentiation, and apoptosis, as well as its low
toxicity. Retinoic acid receptors are not mutated in cancer cells, so
ATRA could potentially exert its anticancer effects in many
malignancies. Nevertheless, to unleash the therapeutic potentials of
ATRA, many studies emphasise the need for a better under-
standing of the mechanisms that block ATRA signalling and
ATRA regulated gene expression in cancer, including AML.
It is evident that combinatorial therapies targeting multiple gene
silencing mechanisms may be the most effective strategy in
reactivating ATRA-sensitive gene expression and differentiation of
AML cells, as well as mediating anticancer activities of ATRA in
general. The identification of classes of proteins that control gene
expression via histone and DNA modifications is driving the
development of new therapeutic agents, the so-called ‘epi-drugs’,
that alter chromatin structure. These epigenetic modifying drugs
have been shown to be only partly effective against different cancers
when used alone. In the context of non-APL AML, epi-drugs such as
LSD1 inhibitors are most effective when combined with ATRA and
vice versa. Further explorations of such combinatorial strategies may
very well unravel multiple novel pathways/targets to unlock and
rejuvenate the potential of ATRA in anticancer therapy.
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